

The ECMOCYP (cytochromes P450 Activity) Study

NCT06662084

Status	RECRUITING
Sponsor	University Hospital, Geneva
Enrollment	46 participants

Key Eligibility Criteria

Inclusion (5)

- Male and female patients presenting a refractory cardiogenic shock, requiring temporary mechanical circulatory support (tMCS), with either the use of veno-arterial extracorporeal membrane oxygenation (VA-ECMO) or a micro-axial pump device (Impella® CP).
- Male and female patients in cardiogenic shock according to the SCAI (Society for Cardiovascular Angiography and Interventions) ESC (European Society of Cardiology) definition and not requiring or not eligible to temporary mechanical circulatory support (tMCS). (e.g. ECMO, Impella®, intra-aortic balloon pump) (control group)
- Age \geq 18 years old
- Comprehension of French
- Ability to give consent (consent will be sought from the therapeutic representative or from relatives as the patient will be sedated and intubated. Definitive consent will be sought at patient's second blood sample planned after tMCS explantation (in case of patient's favorable outcome).

Exclusion (6)

- Male and female patients presenting a refractory ARDS requiring veno-venous extracorporeal membrane oxygenation (VV-ECMO)
- Inability to receive the Geneva cocktail by enteral way
- Severe or terminal Renal impairment (defined as $GFR < 30$ ml/min according to Cockcroft-Gault)
- Severe chronic hepatic insufficiency (CHILD B-C)
- Sensitivity to any of the drugs used in the Geneva Cocktail
- ... and 1 more (see full listing online)

Locations (1 total)

University Hospital Of Geneva, Geneva, Switzerland